The worlds leading CDMO for Microbiome therapeuthics
and next generation probiotics.
Developing and producing Bacteria
as a drug for over 70 years

commitment
agility
responsibility
expertise

biose® INDUSTRIE
Your global **CDMO** for **Microbiome Therapeutics**

One single partner

PROCESS DEVELOPMENT

Microbiotic candidates

Aerobic & anaerobic
Consortia & multi or single-strains
Commensal and delivery GMO
Post-biotic

R&D Microbiology Platform

Risk group assessment (Bioinformatics)
Strain Isolation & characterization: Screening,
Strain-specific ID (Molecular tools), Strain characterization
Analytical methods transfer development & validation

R&D Process Platform

Manufacturability screening and process development
Fermenters: 0.5L, 2L, 5L, 20L, 150L
Centrifugation & TFF
Freeze-driers : 2 x 0.5m^2 - 1.5m^2 - 4m^2
Dosage form: Capsule, tablet, sticks, oil-suspension, cream
Powder & Product characterization
Comparability tests

commitment
agility
responsibility
expertise

120 M€ invested to maintain our position as the world leading CDMO for microbiome therapeutics and next generation probiotics

GMP DRUG PRODUCTION

DRUG SUBSTANCE

Scale-up & manufacturing

GMP MCB and WCB manufacturing / according to LBP Guidelines and storage at -80°c & -20°c

DS1 : 300L and 3 500L - Centrifugation & TFF + 25m² freeze-dryer

DS2 : 2 000L - Concentration + 6m² freeze-dryer

DS3 : 4 x 800L - 2x 30m² freeze-dryer

DS4 : 150L - Centrifugation + 1m² freeze-dryer

DS5 : 2 000L - Centrifugation + 12m² freeze-dryer

DS6 : 5 000L - Centrifugation + 30m² freeze-dryer

Commercial or clinical batches released by our QP (PharmD)

Powder placebo production for Capsule & Tablet & Sachet

DRUG PRODUCT

Formulation for Capsules/ Tablets/Sachets / Oils & Creams

Blending from 10 to 400 kg

Dosage forms : Capsules, Tablets, Powder

Enteric Banding and Coating

Packaging : Blisters, Vials, Sachets, Tubes, Creams & Oils.

biose® INDUSTRIE

Your global CDMO for Microbiome Therapeutics



KEY FIGURES

+ 766 DS batches released in 2023

+ 318 DP batches released in 2023

+ 75 Tonnes of commercial drug substance

160 000 QC analyses done in 2023

52000m² centre of excellence + applied R&D laboratory in Boston, US.

30+ clinical lines including 3x phase III projects in Asia, Europe & the US for Microbiome therapeutics and next generation probiotics

Contact : Richard Ellis Head of Business Development

+ 33 **6 40 97 03 20** - **r.ellis@biose.com**

Main facility, R&D and GMP production - Aurillac France

R&D and Pilot Plant - Boston USA

www.biose.com